Publications by authors named "Dijia Xin"
Article Synopsis
- BCMA CAR T cell therapy has been approved to treat relapsed and refractory multiple myeloma (RRMM), but long-term response effectiveness remains unclear.
- The study examined a new therapy called CBG-002, designed to improve treatment outcomes in RRMM, with a focus on safety and efficacy through a phase I clinical trial involving 11 patients.
- Results showed that CBG-002 was generally safe, with most patients experiencing mild side effects, and a significant overall response rate of 81.8%, indicating potential effectiveness for RRMM treatment, along with a median duration of response of 8.9 months.
Article Synopsis
- Although advancements in targeted drugs for acute myeloid leukemia (AML) have been made, chemotherapy remains the primary treatment and overall patient survival rates are still low.
- A novel compound, NL101, shows promise in treating AML by inhibiting the growth of leukemia cells, causing DNA damage, and triggering apoptosis through a specific gene's involvement.
- The study suggests that the PTEN gene plays a crucial role in how well AML cells respond to NL101, and combining NL101 with rapamycin could enhance treatment effectiveness.
Radiation-induced cerebral necrosis, also known as radiation encephalopathy, is a debilitating condition that significantly impacts the quality of life for affected patients. Secondary central nervous system lymphoma (SCNSL) typically arises from highly aggressive mature B-cell lymphoma, but rarely from extranodal natural killer T-cell lymphoma (ENKTL). Treatment will be guided by differentiation between lymphoma progression from brain necrosis, and is particularly important for critically ill patients in an acute setting.
View Article and Find Full Text PDFBackground: Multiple myeloma (MM) is a clonal plasma cell disorder which still lacks sufficient prognostic factors. The serine/arginine-rich splicing factor (SRSF) family serves as an important splicing regulator in organ development. Among all members, SRSF1 plays an important role in cell proliferation and renewal.
View Article and Find Full Text PDFPurpose: Colon adenocarcinoma (COAD) is the most common type of colorectal cancer (CRC) and is associated with poor prognosis. Emerging evidence has demonstrated that glycosylation by long noncoding RNAs (lncRNAs) was associated with COAD progression. To date, however, the prognostic values of glycosyltransferase (GT)-related lncRNAs in COAD are still largely unknown.
View Article and Find Full Text PDFOver the last two decades, several epi-drugs, immune checkpoint inhibitors (ICIs) and adoptive cell therapies have received clinical approval for use in certain types of cancer. However, monotherapy with epi-drugs or ICIs has shown limited efficacy in most cancer patients. Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion, suggesting that epi-drugs can potentially synergize with immunotherapy.
View Article and Find Full Text PDF